Comparative Pharmacology
Head-to-head clinical analysis: SINEQUAN versus TOFRANIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SINEQUAN versus TOFRANIL.
SINEQUAN vs TOFRANIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits reuptake of serotonin and norepinephrine in the CNS; also has anticholinergic, antihistaminergic, and sedative effects.
Inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing synaptic concentrations of these neurotransmitters. Metabolite desipramine is more selective for norepinephrine reuptake inhibition.
Initial: 50-150 mg/day PO divided 1-3 times daily; max 300 mg/day. Maintenance: lowest effective dose.
Initial: 75-150 mg/day orally in divided doses; maintenance: 50-150 mg/day; maximum: 200 mg/day. For depression, dose may be increased gradually to 300 mg/day if needed.
None Documented
None Documented
Terminal elimination half-life: 8–24 hours (parent drug); steady state achieved in 2–4 weeks; clinical context: may require dose adjustment in hepatic impairment.
Terminal elimination half-life 8–20 hours (mean 12 hours); clinical context: steady-state achieved in 3–7 days; active metabolite desipramine half-life 12–28 hours.
Renal (approximately 30-40% as unchanged drug, with extensive hepatic metabolism to metabolites; minor biliary/fecal excretion).
Primarily renal (70% as metabolites, <5% unchanged); 20% biliary/fecal.
Category C
Category C
Tricyclic antidepressant
Tricyclic antidepressant